An open-label trial of memantine for the treatment of posttraumatic stress disorder
- Conditions
- posttraumatic stress disorder
- Registration Number
- JPRN-UMIN000022467
- Lead Sponsor
- ational Institute of Mental Health, National Center of Neurology and Psychiatry
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up continuing
- Sex
- All
- Target Recruitment
- 20
Not provided
(1) Patients with duration of illness less than 6 months (2) Individuals who received specific psychotherapy (e.g., prolonged exposure therapy, cognitive processing therapy, and eye movement desensitization and reprocessing therapy) within 3 months prior to the recruitment into the study (3) Patients with comorbid schizophrenia, severe manic phase of bipolar disorder, or intellectual disability (4) Individuals with serious suicidal ideation (5) Individuals with severe physical illnesses that can interfere with study participation (6) Pregnant women (7) Individuals with the following physical conditions that are described in manufacturer's package insert as "careful administration": -History of epilepsy or convulsion -Renal dysfunction -Factors increasing urine pH -Severe liver dysfunction (8) Patients considered unqualified for the study by their attending physicians
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method